GSK · Physical Exposure and Transition

Active ingredient synthesis is the largest S3 bucket. Decarbonisation pace of bulk chemicals + fine chemicals manufacturers in Asia caps progress.

GSK's largest Scope 3 exposure sits with upstream API and fine chemical suppliers, whose synthesis and wastewater discharge practices drive both carbon and AMR-related environmental risk [E1][E4]. As GSK widens its monitoring net to more API suppliers, compliance rates on wastewater discharge limits have mechanically dropped from 94% to 87%, reflecting broader scope rather than worse underlying performance, and underscoring how fragmented and opaque this supplier base still is [E4][E5]. Historically, GSK has also lacked a full 15-category Scope 3 emissions picture at publication time, limiting visibility into API-linked purchased goods emissions specifically [E6][E8].

GSK launched a Sustainable Procurement Programme in September 2022 requiring suppliers to act on carbon, power, heat, transport, water and waste, with a 2023 requirement for suppliers to disclose emissions and set 1.5°C-aligned reduction targets — directly targeting the API and chemicals supply chain named in this pathway [E1][E2][E3]. It has also expanded wastewater API discharge-limit monitoring to a larger supplier population, improving transparency into environmental compliance even as reported compliance percentages temporarily fell due to widened scope [E4][E5]. These supplier-facing measures sit alongside GSK's SBTi-aligned Scope 3 targets (80% reduction by 2030, 90% by 2045 from a 2020 base), though no evidence details specific decarbonisation programmes with named API or bulk chemical manufacturers.

Cold-chain HFC leaks + MDI propellants. Kigali Amendment phase-down sets the schedule.

GSK's material HFC exposure is concentrated in patient use-of-inhaler propellant emissions rather than cold-chain refrigerant leaks: in 2020 this single use-phase category was reported at 5,757 kt CO2e, dwarfing all other disclosed Scope 3 lines that year [E1]. Ventolin, GSK's HFA134a-propellant metered-dose inhaler, alone accounts for roughly 43% of the company's total carbon footprint, making MDI propellant chemistry the dominant driver of this pathway rather than a peripheral logistics issue [E2]. Broader Scope 3 category data (categories 1-15) has repeatedly been unavailable at the time of annual/sustainability report publication across 2020-2023, limiting visibility into how propellant emissions trend against other value-chain sources [E3][E4][E5][E6][E7][E8].

GSK's core response is reformulation: it has reported positive Phase III pivotal data for a next-generation low-carbon Ventolin MDI using HFA-152a propellant, cutting per-inhaler carbon footprint by 92% versus the current HFA134a version, with regulatory submissions underway and launch targeted from 2026 [E2]. This propellant switch is the company's primary lever against its largest Scope 3 use-phase source, given Ventolin's ~43% share of total footprint [E2]. Beyond this named reformulation programme, GSK's SBTi-validated targets commit to 80% Scope 1+2 reduction by 2030 and 90% by 2045, and 80% Scope 3 reduction by 2030 (90% by 2045) against a 2020 baseline, though these targets are not propellant-specific and the evidence provides no additional disclosed detail on cold-chain HFC refrigerant management [E1].

Clinical trial sample shipping + global team travel. Cold-chain air freight is doubly energy-intensive.

GSK's aviation exposure sits within Scope 3 categories 4/9 (upstream and downstream transportation and distribution) and business travel, covering clinical trial sample shipping, cold-chain air freight of medicines and vaccines, and global team travel [E1][E2][E3][E4]. The company has not disclosed operational specifics such as air freight volumes, trial shipment counts, or travel mileage in the evidence reviewed, and full Scope 3 category data has repeatedly been unavailable at the time of annual/sustainability report publication (2020, 2021, 2023), limiting visibility into the scale of aviation-linked emissions [E5][E6][E7][E8].

GSK has set an SBTi-aligned Scope 3 target to cut absolute emissions from categories including upstream transportation and distribution and business travel 80% by 2030 and 90% by 2045 against a 2020 baseline, as part of its net-zero-by-2045 value-chain commitment. Beyond target-setting, the evidence shows methodological work reclassifying transportation emissions from downstream to upstream on Carbon Trust advice [E1][E2][E3][E4], but no disclosed programme specifically addressing air freight, cold-chain logistics, or business travel reduction measures is present in the extracted reports. Reported Scope 3 data gaps in multiple years [E5][E6][E7][E8] also mean progress against the aviation-relevant portion of the target cannot currently be verified from disclosed figures.